{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:22Z","timestamp":1791994582268,"version":"4.4.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3601800"],"award-info":[{"award-number":["2022YFC3601800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2022YFC3601800"],"award-info":[{"award-number":["2022YFC3601800"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82430102"],"award-info":[{"award-number":["82430102"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32141004"],"award-info":[{"award-number":["32141004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-I2M-1-059"],"award-info":[{"award-number":["2021-I2M-1-059"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences & Peking Union Medical College","doi-asserted-by":"publisher","award":["2020-RC320-003"],"award-info":[{"award-number":["2020-RC320-003"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.coi.2025.102589","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T19:48:04Z","timestamp":1750362484000},"page":"102589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Can we cure bullous skin diseases?"],"prefix":"10.1016","volume":"95","author":[{"given":"Sicheng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianjin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102589_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"Bmj"},{"key":"10.1016\/j.coi.2025.102589_bib2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12026-018-8986-7","article-title":"Pemphigus group: overview, epidemiology, mortality, and comorbidities","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol Res"},{"key":"10.1016\/j.coi.2025.102589_bib3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaad.2013.05.016","article-title":"Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids","volume":"69","author":"Almugairen","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib4","doi-asserted-by":"crossref","DOI":"10.1007\/s13555-012-0017-3","article-title":"Rituximab in the treatment of pemphigus vulgaris","volume":"2","author":"Zakka","year":"2012","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.coi.2025.102589_bib5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/07853890.2018.1443346","article-title":"Relapse of bullous pemphigoid: an update on this stubborn clinical problem","volume":"50","author":"Wang","year":"2018","journal-title":"Ann Med"},{"key":"10.1016\/j.coi.2025.102589_bib6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0923-1811(00)00158-4","article-title":"Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus","volume":"26","author":"Futei","year":"2001","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.coi.2025.102589_bib7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/1523-1747.ep12319948","article-title":"Pharmacologic evidence for involvement of phospholipase C in pemphigus IgG-induced inositol 1,4,5-trisphosphate generation, intracellular calcium increase, and plasminogen activator secretion in DJM-1 cells, a squamous cell carcinoma line","volume":"105","author":"Esaki","year":"1995","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib8","doi-asserted-by":"crossref","first-page":"8936","DOI":"10.1074\/jbc.M109.087999","article-title":"p38MAPK signaling and desmoglein-3 internalization are linked events in pemphigus acantholysis","volume":"285","author":"Jolly","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coi.2025.102589_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.701809","article-title":"Autoantibody-specific signalling in pemphigus","volume":"8","author":"Schmitt","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.coi.2025.102589_bib10","first-page":"134","article-title":"Atypical pemphigus: autoimmunity against desmocollins and other non-desmoglein autoantigens","volume":"156","author":"Gualtieri","year":"2021","journal-title":"Ital J Dermatol Venerol"},{"key":"10.1016\/j.coi.2025.102589_bib11","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.celrep.2019.06.066","article-title":"Single-cell analysis suggests that ongoing affinity maturation drives the emergence of pemphigus vulgaris autoimmune disease","volume":"28","author":"Cho","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.coi.2025.102589_bib12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jid.2019.07.717","article-title":"Autoreactive B cell differentiation in diffuse ectopic lymphoid-like structures of inflamed pemphigus lesions","volume":"140","author":"Zhou","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jid.2019.08.430","article-title":"Is local production of autoantibodies in skin lesions relevant in pemphigus?","volume":"140","author":"Nomura","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103128","article-title":"Integrative single-cell analysis reveals distinct adaptive immune signatures in the cutaneous lesions of pemphigus","volume":"142","author":"Xu","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102589_bib15","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221717","article-title":"Progressive differentiation toward the long-lived plasma cell compartment in the bone marrow","volume":"220","author":"Koike","year":"2023","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2025.102589_bib16","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1111\/1346-8138.17505","article-title":"Pemphigus relapse: mechanisms, risk factors, and agents associated with disease recurrence","volume":"51","author":"Pathak","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaad.2006.06.007","article-title":"Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies","volume":"56","author":"Cummins","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib18","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1172\/JCI57379","article-title":"Desmoglein 3-specific CD4+ T cells induce pemphigus vulgaris and interface dermatitis in mice","volume":"121","author":"Takahashi","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2025.102589_bib19","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jaci.2020.03.036","article-title":"Targeting inducible costimulator expressed on CXCR5(+)PD-1(+) T(H) cells suppresses the progression of pemphigus vulgaris","volume":"146","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2025.102589_bib20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000099585","article-title":"CD4+CD25high regulatory T cells are markedly decreased in blood of patients with pemphigus vulgaris","volume":"214","author":"Sugiyama","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.coi.2025.102589_bib21","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2026763118","article-title":"Peripheral tolerance by Treg via constraining OX40 signal in autoreactive T cells against desmoglein 3, a target antigen in pemphigus","volume":"118","author":"Iriki","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coi.2025.102589_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/jid.2013.224","article-title":"MAPKAP kinase 2 (MK2)-dependent and -independent models of blister formation in pemphigus vulgaris","volume":"134","author":"Mao","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib23","doi-asserted-by":"crossref","first-page":"9447","DOI":"10.1074\/jbc.M112.438010","article-title":"A pathophysiologic role for epidermal growth factor receptor in pemphigus acantholysis","volume":"288","author":"Bektas","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coi.2025.102589_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/exd.15184","article-title":"Proteomic analysis reveals oxidative phosphorylation and JAK-STAT pathways mediated pathogenesis of pemphigus vulgaris","volume":"33","author":"Cheng","year":"2024","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib25","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.4049\/jimmunol.151.10.5742","article-title":"Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain","volume":"151","author":"Giudice","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2025.102589_bib26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/1523-1747.ep12507222","article-title":"An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement","volume":"78","author":"Gammon","year":"1982","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib27","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1172\/JCI117826","article-title":"The role of complement in experimental bullous pemphigoid","volume":"95","author":"Liu","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2025.102589_bib28","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1046\/j.0022-202x.2001.01521.x","article-title":"Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid","volume":"117","author":"Verraes","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib29","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/jdv.16996","article-title":"IgE autoantibodies in serum and skin of non-bullous and bullous pemphigoid patients","volume":"35","author":"Lamberts","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coi.2025.102589_bib30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2133.2000.03661.x","article-title":"IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis","volume":"143","author":"Christophoridis","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102589_sbref31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jid.2022.08.041","article-title":"CXCL12\/CXCR4 axis drives the chemotaxis and differentiation of B cells in bullous pemphigoid","volume":"143","author":"Fang","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib32","article-title":"Bullous pemphigoid: the role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102589_bib33","article-title":"Type XVII collagen-specific CD4(+) T cells induce bullous pemphigoid by producing IL-5","volume":"145","author":"Yoshimoto","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib34","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1038\/jid.2014.263","article-title":"Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid","volume":"134","author":"Le Jan","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2018.09.003","article-title":"IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid","volume":"96","author":"Chakievska","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102589_bib36","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1523-1747.2000.00141.x","article-title":"Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes","volume":"115","author":"Schmidt","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib37","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00003-2015","article-title":"Trans-basement membrane migration of eosinophils induced by LPS-stimulated neutrophils from human peripheral blood in vitro","volume":"1","author":"Nishihara","year":"2015","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.coi.2025.102589_sbref38","doi-asserted-by":"crossref","DOI":"10.3390\/biom13071019","article-title":"Eosinophils, basophils, and neutrophils in bullous pemphigoid","volume":"13","author":"Limberg","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.coi.2025.102589_bib39","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102589_bib40","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/bjd\/ljad369","article-title":"Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients","volume":"190","author":"Chebani","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib41","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102589_bib42","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.bmt.1704679","article-title":"High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory pemphigus foliaceus","volume":"34","author":"Oyama","year":"2004","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.coi.2025.102589_bib43","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/ijd.13461","article-title":"Application of autologous hematopoietic stem cell transplantation for pemphigus","volume":"56","author":"Wang","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.coi.2025.102589_sbref44","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/bjd\/ljae107","article-title":"Beyond the skin: B cells in pemphigus vulgaris, tolerance and treatment","volume":"191","author":"Strandmoe","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib45","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/jid.2014.291","article-title":"Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years","volume":"135","author":"Hammers","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib46","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40257-019-00497-9","article-title":"Rituximab: a review in pemphigus vulgaris","volume":"21","author":"Frampton","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib47","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102589_bib48","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1111\/jdv.18686","article-title":"Dyshidrosiform pemphigoid induced by ustekinumab in a patient with ulcerative colitis","volume":"37","author":"Didona","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coi.2025.102589_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15207","article-title":"Guselkumab-associated bullous pemphigoid in a psoriasis patient: a case report and review of the literature","volume":"35","author":"Burlando","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.coi.2025.102589_bib50","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/jvc2.444","article-title":"Risk of adverse events in patients with bullous pemphigoid treated with oral corticosteroids in the United States","volume":"3","author":"Silverberg","year":"2024","journal-title":"JEADV Clin Pract"},{"key":"10.1016\/j.coi.2025.102589_bib51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jdin.2022.07.005","article-title":"Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic review","volume":"9","author":"Zeng","year":"2022","journal-title":"JAAD Int"},{"key":"10.1016\/j.coi.2025.102589_bib52","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/ijd.14647","article-title":"Drug adherence in patients with autoimmune vesiculobullous disorders - a cross sectional study","volume":"59","author":"Kv","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.coi.2025.102589_sbref53","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41573-024-00959-8","article-title":"Sequential immunotherapy: towards cures for autoimmunity","volume":"23","author":"Ram\u00edrez-Valle","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coi.2025.102589_bib54","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1084\/jem.186.5.777","article-title":"Beta2-microglobulin-deficient mice are resistant to bullous pemphigoid","volume":"186","author":"Liu","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2025.102589_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.863095","article-title":"FcRn antagonism leads to a decrease of desmoglein-specific B cells: secondary analysis of a phase 2 study of efgartigimod in pemphigus vulgaris and pemphigus foliaceus","volume":"13","author":"Maho-Vaillant","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102589_bib56","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/bph.14986","article-title":"Treatment with anti-neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice","volume":"177","author":"Kasprick","year":"2020","journal-title":"Br J Pharm"},{"key":"10.1016\/j.coi.2025.102589_bib57","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1016\/j.jid.2024.02.038","article-title":"Intravenous Ig ameliorates disease in a murine model of anti-laminin 332 mucous membrane pemphigoid","volume":"144","author":"Murthy","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib58","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjd.20782","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib59","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.smim.2018.03.002","article-title":"The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin","volume":"37","author":"Sadik","year":"2018","journal-title":"Semin Immunol"},{"key":"10.1016\/j.coi.2025.102589_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2024.100307","article-title":"Treatment of bullous pemphigoid with avdoralimab: multicenter, randomized, open-labeled phase 2 study","volume":"4","author":"Passeron","year":"2024","journal-title":"JID Innov"},{"key":"10.1016\/j.coi.2025.102589_bib61","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of dupilumab in patients with bullous pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib62","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/bjd\/ljae403","article-title":"Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicenter case series","volume":"192","author":"Planella-Fontanillas","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102589_bib63","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1007\/s12325-024-02810-3","article-title":"Study design of a phase 2\/3 randomized controlled trial of dupilumab in adults with bullous pemphigoid: LIBERTY-BP ADEPT","volume":"41","author":"Murrell","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.coi.2025.102589_bib64","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102589_sbref65","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.coi.2025.102589_bib66","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.coi.2025.102589_bib67","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2025.102589_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/s41422-025-01128-1","article-title":"Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus","author":"Yang","year":"2025","journal-title":"Cell Res"},{"key":"10.1016\/j.coi.2025.102589_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108733","article-title":"Plasma cell dynamics in the bone marrow niche","volume":"34","author":"Benet","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.coi.2025.102589_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2015.10.006","article-title":"Treatment of murine lupus with PD-LIg","volume":"162","author":"Zhou","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coi.2025.102589_bib71","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","article-title":"A phase 2 trial of peresolimab for adults with rheumatoid arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102589_bib72","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102589_sbref73","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell-engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102589_bib74","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.285343","article-title":"New bispecific antibodies in diffuse large B-cell lymphoma","author":"Minson","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.coi.2025.102589_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-46448-9","article-title":"Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus","volume":"15","author":"Doglio","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102589_bib76","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-024-03262-w","article-title":"MOG-specific CAR Tregs: a novel approach to treat multiple sclerosis","volume":"21","author":"Frikeche","year":"2024","journal-title":"J Neuroinflamm"},{"key":"10.1016\/j.coi.2025.102589_sbref77","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.immuni.2024.07.016","article-title":"Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics","volume":"57","author":"Raeber","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2025.102589_bib78","first-page":"1534","article-title":"Combined therapy with CD4+CD25highCD127\u2212 T regulatory cells and anti-CD20 antibody in recent-onset type 1 diabetes is superior to monotherapy: randomized phase I\/II trial","volume":"24","author":"Zieli\u0144ski","year":"2022","journal-title":"Diabetes\u00a0Obes Metab"},{"key":"10.1016\/j.coi.2025.102589_bib79","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41551-023-01086-2","article-title":"Synthetically glycosylated antigens for the antigen-specific suppression of established immune responses","volume":"7","author":"Tremain","year":"2023","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.coi.2025.102589_bib80","article-title":"From insect bites to a skin autoimmune disease: a conceivable pathway to endemic pemphigus foliaceus","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:02:36Z","timestamp":1779084156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525000652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":80,"alternative-id":["S0952791525000652"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102589","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can we cure bullous skin diseases?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102589"}}